Congressional Letter to Administration on Importance of Animal Biotechnology
October 8, 2021
As you know, several challenges facing the agriculture industry and our communities have emerged or intensified in recent years. Zoonotic disease, climate change, and a growing global population require us to consider new solutions to protect our food supply and sustainably meet demand. Ongoing research and existing innovations in animal genetics show great promise in addressing these challenges. However, an efficient, risk and science-based regulatory system that can create a safe, predictable path to market is imperative to capitalizing on these solutions. We believe the existing U.S. regulatory process for the review of animals developed or improved through biotechnology requires significant improvement to meet that standard, and we encourage the U.S. Department of Agriculture (USDA) and Food & Drug Administration (FDA) to continue working with each other and with other relevant federal partners to appropriately modernize this important process.
Download Full Comments Below
Congressional Letter to Administration on Importance of Animal Biotech
Biotechnology Innovation Organization statement for the record to the U.S. House Committee on Small Business Subcommittee on Economic Growth, Tax, and Capital Access hearing on "American Ingenuity: Promoting Innovation Through the Tax Code…
The global IP framework has enabled lifesaving innovation and provides a reliable legal foundation for companies to voluntarily license their IP to enhance research collaborations and provide timely, equitable global access to safe and effective…
As you know, several challenges facing the agriculture industry and our communities have emerged or intensified in recent years. Zoonotic disease, climate change, and a growing global population require us to consider new solutions to protect our food supply and sustainably meet demand. Ongoing research and existing innovations in animal genetics show great promise in addressing these challenges. However, an efficient, risk and science-based regulatory system that can create a safe, predictable path to market is imperative to capitalizing on these solutions. We believe the existing U.S. regulatory process for the review of animals developed or improved through biotechnology requires significant improvement to meet that standard, and we encourage the U.S. Department of Agriculture (USDA) and Food & Drug Administration (FDA) to continue working with each other and with other relevant federal partners to appropriately modernize this important process.